• Optimization of treatment of patients with follicular ovarian cysts

Optimization of treatment of patients with follicular ovarian cysts

HEALTH OF WOMAN. 2017.6(122):124–126; doi 10.15574/HW.2017.122.124

Lakhno I. V., Tkachov A. E., Segal O. S., Zhdanyuk S. O., Ablyazova A. O., Nesmiyan N. V. 
Kharkiv Medical Academy of Postgraduate Education
Kharkiv city perinatal center

The reason of tumor-like ovarian cysts are functional disorders of the hypothalamic-pituitary-ovarian axis which leads to hyperestrogenocity. Medical preparations containing indole-3-carbinol have an evident antiestrogenic effect.

The objective: to study the efficacy of using Mastofemin for the treatment of patients with ovarian cysts.

Patients and methods. The study involved 110 patients of reproductive age, 30 of them were healthy and were included in Group I. There were 38 women with follicular cysts in Group II whom 30 мg of ethinylestradiol-containing combined oral contraceptives in cyclic regimen for 3 months were prescribed. There were 42 patients in Group III who were additionally to combined oral contraceptives prescribed Mastofemin for 1 capsule 2 times daily.

Results. The presence of combined breast pathology and clinical symptoms associated with hyperestrogenocity has been noted in patients with follicular ovarian cysts. The operative treatment due to the lack of effectiveness of the conservative approach was performed in 21.1% of patients in Group II and 7.1% of women in Group III. There was no recurrence of ovarian cysts during further observation within six months in the main Group of patients receiving Mastofemin. 10.5% of women have the reappeared ovarian retention cysts in the Group II.

Conclusion. The use of Mastophemin in addition to combined oral contraceptives for treating women with follicular ovarian cysts contributed to increased compliance and therapeutic efficacy.

Key words: ovarian follicular cysts, indole-3-carbinol, Mastofemin.


1. Sukhanova AA, Melnyk YuM, Karlov OO. 2016. Suchasni pidkhody do likuvannia mastopatii u patsiientok reproduktyvnoho viku. Zdorove zhenshchynы 5:50–56.

2. Enríquez J, Velázquez-Cruz R, Parra-Torres A et al. 2016. The anti-estrogenic activity of indole-3-carbinol in neonatal rat osteoblasts is associated with the estrogen receptor antagonist 2-hydroxyestradiol. J Endocrinol Invest. 39;10:1149–58. https://doi.org/10.1007/s40618-016-0494-9; PMid:27312859

3. Gao X, Petroff BK, Oluola O et al. 2002. Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. Toxicol Appl Pharmacol. 183;3:179–88. https://doi.org/10.1006/taap.2002.9478

4. Kabel AM, Al-Shehri AH, Al-Talhi RA, Abd Elmaaboud MA. 2017. The promising effect of linagliptin and/or indole-3-carbinol on experimentally-induced polycystic ovarian syndrome. Chem Biol Interact. 273:190–199. https://doi.org/10.1016/j.cbi.2017.06.009; PMid:28619389

5. Lawrie TA, Nordin A, Chakrabarti M et al. 2016. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev.1. CD011837. https://doi.org/10.1002/14651858.CD011837.pub2

6. Megna BW, Carney PR, Kennedy GD. 2016. Intestinal inflammation and the diet: Is food friend or foe? World J Gastrointest Surg. 8;2:115–23. https://doi.org/10.4240/wjgs.v8.i2.115; PMid:26981185 PMCid:PMC4770165

7. Meng Q, Yuan F, Goldberg ID et al. 2000. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr. 130;12:2927–31. PMid:11110848

8. Parajuli B, Shin SJ, Kwon SH et al. 2013. The synergistic apoptotic interaction of Indole-3-Carbinol and Genistein with TRAIL on endometrial cancer cells. J Korean Med Sci. 28;4:527–33. https://doi.org/10.3346/jkms.2013.28.4.527; PMid:23580227 PMCid:PMC3617304

9. Pfeifer BL, Fahrendorf T. 2015. Indol-3-Carbinol – ein Glucosinolat-Derivat aus Kreuzblütler-Gemüsen. Deutsche Zeitschrift für Onkologie. 47:20–27. https://doi.org/10.1055/s-0034-1395861

10. Qi M, Anderson AE, Chen DZ et al. 2005. Indole-3-carbinol prevents PTEN loss in cervical cancer in vivo. Mol Med. 11;1:59–63.

11. Taylor-Harding B, Agadjanian H, Nassanian H et al. 2012. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. Br J Cancer. 106;2:333–43. https://doi.org/10.1038/bjc.2011.546; PMid:22166800 PMCid:PMC3261668

12. Thomson CА, Chow HHS, Wertheim BC et al. 2017. A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen. Breast Cancer Res Treat. 165;1:97–107.